Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary AP3 proteomics platform. The company designs targeted cancer therapies and companion OncoSignature diagnostics to identify patients most likely to respond, focusing on tumors beyond genomics-based selection. Its pipeline includes selective inhibitors like ACR-368 and ACR-2316, aimed at treating solid tumors with high unmet needs through biomarker-driven patient stratification and rational drug combinations.
This description was generated via AI from an annual report. Updated about 1 year ago.